NASDAQ:NVTR - Nuvectra Stock Price, Forecast & News

Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."

Nuvectra Corp (NASDAQ:NVTR) announced its earnings results on Monday, October, 29th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.01. The business had revenue of $14.22 million for the quarter, compared to the consensus estimate of $12.38 million. Nuvectra had a negative net margin of 99.08% and a negative return on equity of 58.23%. View Nuvectra's Earnings History.

3 analysts have issued twelve-month target prices for Nuvectra's shares. Their forecasts range from $4.00 to $18.00. On average, they anticipate Nuvectra's share price to reach $10.67 in the next year. This suggests a possible upside of 8,105.1% from the stock's current price. View Analyst Price Targets for Nuvectra.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra.

News coverage about NVTR stock has trended somewhat negative on Wednesday, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nuvectra earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Nuvectra.

Some companies that are related to Nuvectra include PlusTherapeuticsInc . (PSTV), Dynatronics (DYNT), Hancock Jaffe Laboratories (HJLI), CELLECT BIOTECH/S (APOP), Valeritas (VLRX), Encision (ECIA), Neurometrix (NURO), Invivo Therapeutics (NVIV), Sintx Technologies (SINT), AdvanSource Biomaterials Corpration (ASNB), Regenicin (RGIN), Cytocore (MDIT), United American Healthcare (UAHC), Hypertension Diagnostics (HDII) and TearLab (TEAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nuvectra investors own include Allena Pharmaceuticals (ALNA), NovaBay Pharmaceuticals (NBY), Aldeyra Therapeutics (ALDX), Avinger (AVGR), Biocept (BIOC), Deciphera Pharmaceuticals (DCPH), Fate Therapeutics (FATE), Iovance Biotherapeutics (IOVA), Rigel Pharmaceuticals (RIGL) and Ampliphi Biosciences (APHB).

Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVTR stock can currently be purchased for approximately $0.13.

Nuvectra has a market capitalization of $2.33 million and generates $48.83 million in revenue each year. The company earns $-48,130,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Nuvectra employs 197 workers across the globe.View Additional Information About Nuvectra.

The official website for Nuvectra is http://www.nuvectramed.com/.

Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]